Anavex Life Sciences Corp (AVXL)
9.035
+0.56
(+6.61%)
USD |
NASDAQ |
Nov 21, 16:00
9.035
0.00 (0.00%)
After-Hours: 20:00
Anavex Life Sciences Enterprise Value: 579.89M for Nov. 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2024 | 579.89M |
| November 19, 2024 | 559.96M |
| November 18, 2024 | 492.97M |
| November 15, 2024 | 492.55M |
| November 14, 2024 | 542.15M |
| November 13, 2024 | 615.08M |
| November 12, 2024 | 626.10M |
| November 11, 2024 | 637.12M |
| November 08, 2024 | 644.75M |
| November 07, 2024 | 508.66M |
| November 06, 2024 | 521.80M |
| November 05, 2024 | 514.17M |
| November 04, 2024 | 480.25M |
| November 01, 2024 | 440.82M |
| October 31, 2024 | 422.59M |
| October 30, 2024 | 345.43M |
| October 29, 2024 | 345.85M |
| October 28, 2024 | 351.36M |
| October 25, 2024 | 305.57M |
| October 24, 2024 | 313.20M |
| October 23, 2024 | 318.29M |
| October 22, 2024 | 339.49M |
| October 21, 2024 | 323.38M |
| October 18, 2024 | 340.34M |
| October 17, 2024 | 328.04M |
| Date | Value |
|---|---|
| October 16, 2024 | 329.74M |
| October 15, 2024 | 318.29M |
| October 14, 2024 | 319.99M |
| October 11, 2024 | 317.44M |
| October 10, 2024 | 294.55M |
| October 09, 2024 | 296.24M |
| October 08, 2024 | 305.57M |
| October 07, 2024 | 316.60M |
| October 04, 2024 | 335.67M |
| October 03, 2024 | 336.10M |
| October 02, 2024 | 340.76M |
| October 01, 2024 | 322.53M |
| September 30, 2024 | 342.88M |
| September 27, 2024 | 342.88M |
| September 26, 2024 | 342.03M |
| September 25, 2024 | 323.38M |
| September 24, 2024 | 332.71M |
| September 23, 2024 | 326.77M |
| September 20, 2024 | 339.49M |
| September 19, 2024 | 349.67M |
| September 18, 2024 | 327.62M |
| September 17, 2024 | 324.23M |
| September 16, 2024 | 344.58M |
| September 13, 2024 | 311.51M |
| September 12, 2024 | 303.03M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
99.44M
Minimum
Nov 22 2019
2.014B
Maximum
Jun 28 2021
559.39M
Average
498.85M
Median
Apr 17 2023
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 2.745M |
| Palatin Technologies Inc | 15.49M |
| iBio Inc | 9.932M |
| Theriva Biologics Inc | -12.74M |
| Oragenics Inc | 2.485M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -12.21M |
| Total Expenses (Quarterly) | 14.73M |
| EPS Diluted (Quarterly) | -0.14 |
| Earnings Yield | -5.64% |